CABG off-pump, same results at one year-pump surgery.

The relative benefits and risks of off-pump coronary artery bypass grafting (CABG) as compared with the use of CBP are not clearly defined. The CORONARY trial in 79 centers randomized 4,752 patients in whom CABG was planned with or without CBP. There was no significant difference in the primary end point which was a composite of death, MI, stroke or new renal failure requiring dialysis at thirty days after randomization. 

The study showed no significant difference in the rate of the primary endpoint between the groups with or without CBP, (9.8% versus 10.3%, p = 0.59), or any of its individual components. Off- pump significantly reduced transfusion requirements, (50.7% versus 63.3%, relative risk 0.80, 95% CI, 0.75 to 0, 85, P <0.001), reoperation for intraoperative bleeding, (1.4% versus 2.4%, relative risk 0.61, 95% CI, 0.40 to 0.93, P = 0.02), acute kidney injury, (28.0% versus 32.1%, relative risk 0 , 87, 95% CI, 0.80 to 0.96, p = 0.01), and respiratory complications, (5.9% versus 7.5%, relative risk 0.79, 95% CI, 0.63 – 98, P = 0 , 03), but increased the initial rate of revascularization, (0.7% versus 0.2%, relative risk, 4.01, 95% CI, 1.34 to 12.0, p = 0.01). There were no significant differences in the rate of death, myocardial infarction, stroke or renal failure requiring dialysis after thirty days.

Comments: Off- pump surgery technique is the most used in the United States and is the easiest to perform according to Dr. Lamy. Despite some favorable outcomes for off-pump surgery, the results of evolution to one year failed to confirm this benefit. Patients under EuroSCORE are not candidates for CBP and high-risk patients seem to benefit more from surgery with CBP according to Dr. Lamy. 

Read article

andre_lamy_acc2013_presentacion
Andre Lamy
2013-03-11

Original title: CORONARY: The Coronary Artery Bypass Grafting Surgery Off or On Pump Revascularization Study. Results at 1 year. 

More articles by this author

PARTNER cohort A at three years, the benefit continues

The PARTNER Cohort A randomized 699 elderly patients, (mean age 84.1), with severe aortic stenosis for TAVI or conventional surgery in 26 centers. The...

ASTRONAUT: Aliskiren failed to show benefits in patients with acute heart failure

Hospitalization for heart failure, (HF), represents a major health problem with high rates of death or early readmission after discharge. The aim of this...

RELAX Study: Phosphodieserase-5 inhibitors showed no benefit in heart failure with preserved ventricular function.

Phosphodieserase-5 enzyme is activated in heart failure and can limit the beneficial effects of nitric oxide, (NO), in the vasculature, kidney and myocardium. The...

STOP-HF: The use of B-type natriuretic peptide (BNP) for screening high-risk population decreases the prevalence of heart failure

B-type natriuretic peptide (BNP) can be a reliable marker for the diagnosis of heart failure (HF). This study aimed to assess whether the use...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....